SWOG-9023, DNA Analysis of Tumor Tissue From Patients With Metastatic Kidney Cancer

NCT00900042 | Completed

• 3 other identifiers: CDR0000502305SWOG-9023U10CA032102
• Study Type: observational
• Target: 34
• Locations: 0 countries
• Sites: N/A

Brief Summary

RATIONALE: DNA analysis of tumor tissue may help doctors predict how well patients will respond to treatment. PURPOSE: This laboratory study is analyzing the DNA in tumor tissue from patients with metastatic kidney cancer.

Conditions

Kidney Cancer

Keywords

stage IV renal cell cancer

Outcome Measures

Primary Outcomes (5)

• Number of successes per number of evaluable samples

  Success is defined as obtaining at least 10 analyzable metaphases.

  up to 4 years after registration

• Number of abnormalities per number of successes

  Abnormality is defined as at lease one clonal chromosomal abnormality.

  up to 4 years after registration

• Correlation of tumor response to treatment with the type and number of abnormalities

  Abnormality is defined as at lease one clonal chromosomal abnormality.

  up to 4 years after registration

• Correlation of time from diagnosis to development of metastatic disease with the type and number of abnormalities

  Abnormality is defined as at lease one clonal chromosomal abnormality.

  up to 4 years after registration

• Correlation of time from first diagnosis of metastatic disease until death with the type and number of abnormalities

  Abnormality is defined as at lease one clonal chromosomal abnormality.

  up to 4 years after registration

Interventions

DNA ploidy analysis GENETIC

DNA stability analysis GENETIC

chromosomal translocation analysis GENETIC

cytogenetic analysis GENETIC

flow cytometry OTHER

laboratory biomarker analysis OTHER

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

DISEASE CHARACTERISTICS: * Diagnosis of renal cell carcinoma * Any T, any N, M1 disease as specified in SWOG-8949 * Eligible for and registered on the nephrectomy arm\* (arm I) of SWOG-8949 NOTE: \*Patients must be registered on this study before undergoing nephrectomy on SWOG-8949 PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * See Disease Characteristics

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• SWOG Cancer Research Network: lead
• National Cancer Institute (NCI): collaborator

Biospecimen

Retention: SAMPLES WITH DNA

Tumor diagnostic tissue

MeSH Terms

Conditions

Kidney Neoplasms; Carcinoma, Renal Cell

Interventions

Cytogenetic Analysis; Flow Cytometry

Condition Hierarchy (Ancestors)

Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Kidney Diseases; Urologic Diseases; Male Urogenital Diseases; Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type

Intervention Hierarchy (Ancestors)

Cytological Techniques; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Investigative Techniques; Genetic Techniques; Cell Separation; Cytophotometry; Fluorometry; Luminescent Measurements; Photometry; Chemistry Techniques, Analytical

Study Officials

• Robert P. Whitehead, MD

  University of Texas

  STUDY CHAIR

Study Design

• Study Type: observational
• Time Perspective: PROSPECTIVE
• Sponsor Type: NETWORK
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 9, 2009
• First Posted: May 12, 2009
• Study Start: July 1, 1993
• Primary Completion: December 1, 2002
• Study Completion: January 1, 2003
• Last Updated: February 25, 2014

Record last verified: 2014-02